Clinical Trials
25 trialsNCT03336606 2026-05-22
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
Phase 1 Completed
NCT03370276 2026-04-02
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT03509467 2025-12-19
Using MC1R Genotype to Impact Melanoma Risk Behavior
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT04180215 2025-09-15
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
Hookipa Biotech GmbH
Phase 1/2 Completed
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT04357873 2025-02-19
PEVOsq
UNICANCER
Phase 2 Completed
NCT02164461 2024-05-20
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Advaxis, Inc.
Phase 1 Completed
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT00542308 2023-08-03
Zalutumumab in Non-curable Patients With SCCHN
Genmab
Phase 2 Completed
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT00847912 2021-06-11
VAKCCT
VA Office of Research and Development
Phase 4 Completed
NCT01581970 2019-09-11
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01016769 2019-06-26
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00661427 2018-01-11
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01721525 2017-10-25
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01384708 2016-01-11
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
Anandasabapathy, Sharmila, M.D.
Phase EARLY_PHASE1 Completed
NCT00574977 2015-12-28
Safety Study of Modified Vaccinia Virus to Cancer
University of Pittsburgh
Phase 1 Completed
NCT00815295 2014-12-08
Study of Sorafenib/Cetuximab in Head and Neck Cancer
Duke University
Phase 1/2 Completed
NCT00705016 2014-04-30
ADVANTAGE
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00382031 2013-10-15
Zalutumumab in Patients With Non-curable Head and Neck Cancer
Genmab
Phase 3 Completed
NCT01283906 2013-09-12
MuGard
Access Pharmaceuticals, Inc.
Phase 4 Completed
NCT00485485 2012-08-07
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00507858 2011-09-23
Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00229723 2009-08-04
IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00255476 2009-04-23
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
AstraZeneca
Phase 2 Completed